Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer

R. Russo; I. Bartosek; E. Piazza; A. M. Santi; A. Libretti; S. Garattini

Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer

R. Russo, I. Bartosek, E. Piazza, A. M. Santi, A. Libretti, S. Garattini

Istituto di Ricerche Farmacologiche "Mario Negri"

Research output: Contribution to journal › Article

Abstract

BCNU levels were determined by differential pulse polarography in 12 patients with lung cancer. A simple assay method for submicrogram quantities of nitrosoureas is described. The half-life of BCNU added to plasma in vitro was 1413 mins at 0°C and 12 mins at 37°C during incubation. BCNU kinetics in blood of treated patients was calculated using the two-compartment open model; the half-life of the drug was 1.4 mins in the first phase and 17.8 mins in the second. Mean distribution volume was 2.59 liters/kg and plasma clearance was 16.7 ml/min/kg.

Original language	English
Pages (from-to)	555-562
Number of pages	8
Journal	Cancer Treatment Reports
Volume	65
Issue number	7-8
Publication status	Published - 1981

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

Fingerprint Dive into the research topics of 'Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer'. Together they form a unique fingerprint.

Cite this

@article{e6975abc27614ceb94d456f8d860402c,

title = "Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer",

abstract = "BCNU levels were determined by differential pulse polarography in 12 patients with lung cancer. A simple assay method for submicrogram quantities of nitrosoureas is described. The half-life of BCNU added to plasma in vitro was 1413 mins at 0°C and 12 mins at 37°C during incubation. BCNU kinetics in blood of treated patients was calculated using the two-compartment open model; the half-life of the drug was 1.4 mins in the first phase and 17.8 mins in the second. Mean distribution volume was 2.59 liters/kg and plasma clearance was 16.7 ml/min/kg.",

author = "R. Russo and I. Bartosek and E. Piazza and Santi, {A. M.} and A. Libretti and S. Garattini",

year = "1981",

language = "English",

volume = "65",

pages = "555--562",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "U.S. National Cancer Institute",

number = "7-8",

}

TY - JOUR

T1 - Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer

AU - Russo, R.

AU - Bartosek, I.

AU - Piazza, E.

AU - Santi, A. M.

AU - Libretti, A.

AU - Garattini, S.

PY - 1981

Y1 - 1981

N2 - BCNU levels were determined by differential pulse polarography in 12 patients with lung cancer. A simple assay method for submicrogram quantities of nitrosoureas is described. The half-life of BCNU added to plasma in vitro was 1413 mins at 0°C and 12 mins at 37°C during incubation. BCNU kinetics in blood of treated patients was calculated using the two-compartment open model; the half-life of the drug was 1.4 mins in the first phase and 17.8 mins in the second. Mean distribution volume was 2.59 liters/kg and plasma clearance was 16.7 ml/min/kg.

AB - BCNU levels were determined by differential pulse polarography in 12 patients with lung cancer. A simple assay method for submicrogram quantities of nitrosoureas is described. The half-life of BCNU added to plasma in vitro was 1413 mins at 0°C and 12 mins at 37°C during incubation. BCNU kinetics in blood of treated patients was calculated using the two-compartment open model; the half-life of the drug was 1.4 mins in the first phase and 17.8 mins in the second. Mean distribution volume was 2.59 liters/kg and plasma clearance was 16.7 ml/min/kg.

UR - http://www.scopus.com/inward/record.url?scp=0019425444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019425444&partnerID=8YFLogxK

M3 - Article

C2 - 7248980

AN - SCOPUS:0019425444

VL - 65

SP - 555

EP - 562

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 7-8

ER -